Sepsis

Pediatric Critical Care

Volumn , Issue , 2011, Pages 1413-1429

  Wong, Hector R ^a   Nowak, Jeffrey E ^b   Standage, Stephen W ^c   Flauzino de Oliveira, Cláudio ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884462309     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-07307-3.10103-X     Document Type: Chapter

References (209)

1. Proulx F., Fayon M., Farrell C.A., et al. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 1996, 109(4):1033-1037.
2. Watson R.S., Carcillo J.A., Linde-Zwirble W.T., et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003, 167(5):695-701.
3. Watson R.S., Carcillo J.A. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med 2005, 6(Suppl 3):S3-5.
4. Czaja A.S., Zimmerman J.J., Nathens A.B. Readmission and late mortality after pediatric severe sepsis. Pediatrics 2009, 123(3):849-857.
5. Vermunt L.C., Buysse C.M., Aarsen F.K., et al. Long-term cognitive functioning in children and adolescents who survived septic shock caused by Neisseria meningitidis. Br J Clin Psychol 2009, 48(Pt 2):195-208.
6. Conlon N.P., Breatnach C., O'Hare B.P. Health-related quality of life after prolonged pediatric intensive care unit stay. Pediatr Crit Care Med 2009, 10(1):41-44.
7. Knoester H., Bronner M.B., Bos A.P., Grootenhuis M.A. Quality of life in children three and nine months after discharge from a paediatric intensive care unit: a prospective cohort study. Health Qual Life Outcomes 2008, 6:21.
8. Pollack M.M., Holubkov R., Glass P., et al. Functional Status Scale: new pediatric outcome measure. Pediatrics 2009, 124(1):e18-28.
9. Goldstein B., Giroir B., Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005, 6(1):2-8.
10. Edlich R.F., Cross C.L., Dahlstrom J.J., Long W.B. 3rd: Modern concepts of the diagnosis and treatment of purpura fulminans. J Environ Pathol Toxicol Oncol 2008, 27(3):191-196.
11. Ceneviva G., Paschall J.A., Maffei F., Carcillo J.A. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998, 102(2):e19).
12. Brierley J., Peters M.J. Distinct hemodynamic patterns of septic shock at presentation to pediatric intensive care. Pediatrics 2008, 122(4):752-759.
13. Typpo K.V., Petersen N.J., Hallman D.M. Day 1 multiple organ dysfunction syndrome is associated with poor functional outcome and mortality in the pediatric intensive care unit. Pediatr Crit Care Med 2009, 10(5):562-570.
14. Wilkinson J.D., Pollack M.M., Ruttimann U.E. Outcome of pediatric patients with multiple organ system failure. Crit Care Med 1986, 14(4):271-274.
15. Proulx F., Joyal J.S., Mariscalco M.M. The pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med 2009, 10(1):12-22.
16. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348(2):138-150.
17. Hotchkiss R.S., Coopersmith C.M., McDunn J.E., Ferguson T.A. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009, 15(5):496-497.
18. Marshall J.C., Charbonney E., Gonzalez P.D. The immune system in critical illness. Clin Chest Med 2008, 29(4):605-616. vii.
19. Tapping R.I. Innate immune sensing and activation of cell surface Toll-like receptors. Semin Immunol 2009, 21(4):175-184.
20. Akira S. Innate immunity to pathogens: diversity in receptors for microbial recognition. Immunol Rev 2009, 227(1):5-8.
21. Wheeler D.S., Zingarelli B., Wheeler W.J., Wong H.R. Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov 2009, 3(2):96-112.
22. Zingarelli B., Sheehan M., Wong H.R. Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med 2003, 31(Suppl 1):S105-111.
23. Abraham E. Alterations in cell signaling in sepsis. Clin Infect Dis 2005, 41(Suppl 7):S459-464.
24. Cornell T.T., Shanley T.P. Signal transduction overview. Crit Care Med 2005, 33(Suppl 12):S410-413.
25. Shanley T.P., Vasi N., Denenberg A., Wong H.R. The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J Immunol 2001, 166(2):966-972.
26. Cornell T.T., Hinkovska-Galcheva V., Sun L., et al. Ceramide-dependent PP2A regulation of TNFalpha-induced IL-8 production in respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009, 296(5):L849-856.
27. Mannel D.N., Echtenacher B. TNF in the inflammatory response. Chem Immunol 2000, 74:141-161.
28. Lorente J.A., Marshall J.C. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 2005, 1(Suppl 24):107-119.
29. Dinarello C.A. Interleukin-1beta. Crit Care Med 2005, 33(Suppl 12):S460-462.
30. Calandra T., Gerain J., Heumann D., et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 1991, 91(1):23-29.
31. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993, 54:1-78.
32. Osuchowski M.F., Connett J., Welch K. Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit Care Med 2009, 37(5):1567-1573.
33. Reinhart K., Menges T., Gardlund B., et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001, 29(4):765-769.
34. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12(2):121-127.
35. Strieter R.M., Kunkel S.L., Keane M.P., Standiford T.J. Chemokines in lung injury: Thomas A. NeffLecture. Chest 1999, 116(Suppl 1):103S-110S.
36. Wong H.R., Cvijanovich N., Wheeler D.S. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med 2008, 178(3):276-282.
37. Calandra T., Froidevaux C., Martin C., Roger T. Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis. J Infect Dis 2003, 2(Suppl 187):S385-390.
38. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3(10):791-800.
39. Tschoeke S.K., Oberholzer A., Moldawer L.L. Interleukin-18: a novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med 2006, 34(4):1225-1233.
40. Opal S.M., DePalo V.A. Anti-inflammatory cytokines. Chest 2000, 117(4):1162-1172.
41. Moore K.W., de Waal Malefyt R., Coffman R.L. et al: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
42. Hall M.W., Gavrilin M.A., Knatz N.L. Monocyte mRNA phenotype and adverse outcomes from pediatric multiple organ dysfunction syndrome. Pediatr Res 2007, 62(5):597-603.
43. Monneret G., Finck M.E., Venet F., et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 2004, 95(2):193-198.
44. Wang H., Ward M.F., Sama A.E. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 2009, 32(4):348-357.
45. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285(5425):248-251.
46. Bianchi M.E. HMGB1 loves company. J Leukoc Biol 2009, 86(3):573-576.
47. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81(1):1-5.
48. Wheeler D.S., Fisher L.E., Catravas J.D. Extracellular hsp70 levels in children with septic shock. Pediatr Crit Care Med 2005, 6(3):308-311.
49. Wheeler D.S., Lahni P., Odoms K. Extracellular heat shock protein 60 (Hsp60) levels in children with septic shock. Inflamm Res 2007, 56(5):216-219.
50. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7(9):678-689.
51. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327(6122):524-526.
52. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987, 84(24):9265-9269.
53. Moncada S., Higgs E.A. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 2006, 176(pt 1):213-254.
54. Wong H.R., Carcillo J.A., Burckart G., et al. Increased serum nitrite and nitrate concentrations in children with the sepsis syndrome. Crit Care Med 1995, 23(5):835-842.
55. Wong H.R., Carcillo J.A., Burckart G., Kaplan S.S. Nitric oxide production in critically ill patients. Arch Dis Child 1996, 74(6):482-489.
56. Vincent J.L., Zhang H., Szabo C., Preiser J.C. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 2000, 161(6):1781-1785.
57. Levi M., de Jonge E., van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003, 16(1-2):43-47.
58. Wang L., Bastarache J.A., Ware L.B. The coagulation cascade in sepsis. Curr Pharm Des 2008, 14(19):1860-1869.
59. Hermans P.W., Hibberd M.L., Booy R. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999, 354(9178):556-560.
60. Kornelisse R.F., Hazelzet J.A., Savelkoul H.F., et al. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996, 173(5):1148-1156.
61. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344(10):699-709.
62. Levi M., van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007, 5(Suppl 11):S3.
63. Nadel S., Goldstein B., Williams M.D., et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369(9564):836-843.
64. Nguyen T.C., Carcillo J.A. Bench-to-bedside review: thrombocytopenia-associated multiple organ failure-a newly appreciated syndrome in the critically ill. Crit Care 2006, 10(6):235.
65. Nguyen T.C., Han Y.Y., Kiss J.E., et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med 2008, 36(10):2878-2887.
66. Zingarelli B., Cook J.A. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 2005, 23(5):393-399.
67. Chima R.S., Hake P.W., Piraino G. Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. Crit Care Med 2008, 36(10):2849-2857.
68. Zingarelli B., Hake P.W., O'Connor M., et al. Lung injury after hemorrhage is age dependent: role of peroxisome proliferator-activated receptor gamma. Crit Care Med 2009, 37(6):1978-1987.
69. Kuboki S., Shin T., Huber N. Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. Hepatology 2008, 47(1):215-224.
70. Kaplan J.M., Cook J.A., Hake P.W. 15-Deoxy-delta(12,14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock 2005, 24(1):59-65.
71. Zingarelli B., Sheehan M., Hake P.W. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 2003, 171(12):6827-6837.
72. Kaplan J.M., Denenberg A., Monaco M., et al. Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock. Intensive Care Med 2010, 36(1):123-130.
73. Munford R.S., Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001, 163(2):316-321.
74. Mahidhara R., Billiar T.R. Apoptosis in sepsis. Crit Care Med 2000, 28(Suppl 4):N105-113.
75. Volk H.D., Reinke P., Krausch D. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996, 4(Suppl 22):S474-481.
76. Docke W.D., Randow F., Syrbe U., et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997, 3(6):678-681.
77. Heidecke C.D., Hensler T., Weighardt H., et al. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg 1999, 178(4):288-292.
78. Felmet K.A., Hall M.W., Clark R.S., Jaffe R., Carcillo J.A. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005, 174(6):3765-3772.
79. Hotchkiss R.S., Swanson P.E., Knudson C.M., et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999, 162(7):4148-4156.
80. Wesche D.E., Lomas-Neira J.L., Perl M., et al. Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol 2005, 78(2):325-337.
81. Chung C.S., Song G.Y., Lomas J. Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity. J Leukoc Biol 2003, 74(3):344-351.
82. Chang K.C., Unsinger J., Davis C.G. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. Faseb J 2007, 21(3):708-719.
83. Unsinger J., Herndon J.M., Davis C.G., et al. The role of TCR engagement and activation-induced cell death in sepsis-induced T cell apoptosis. J Immunol 2006, 177(11):7968-7973.
84. Schwulst S.J., Grayson M.H., DiPasco P.J. Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 2006, 177(1):557-565.
85. Hotchkiss R.S., McConnell K.W., Bullok K., et al. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol 2006, 176(9):5471-5477.
86. Hotchkiss R.S., Osmon S.B., Chang K.C. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005, 174(8):5110-5118.
87. Scumpia P.O., Delano M.J., Kelly K.M., et al. Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis. J Immunol 2006, 177(11):7943-7949.
88. Hotchkiss R.S., Swanson P.E., Freeman B.D., et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999, 27(7):1230-1251.
89. Monserrat J., de Pablo R., Prieto A. Using surface molecule expression on lymphocytes to classify septic shock patients. Crit Care 2009, 13(3):412.
90. Wen H., Dou Y., Hogaboam C.M., Kunkel S.L. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 2008, 111(4):1797-1804.
91. Wen H., Schaller M.A., Dou Y. Dendritic cells at the interface of innate and acquired immunity: the role for epigenetic changes. J Leukoc Biol 2008, 83(3):439-446.
92. Cooke G.S., Hill A.V. Genetics of susceptibility to human infectious disease. Nat Rev Genet 2001, 2(12):967-977.
93. Sorensen T.I., Nielsen G.G., Andersen P.K., Teasdale T.W. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988, 318(12):727-732.
94. Arcaroli J., Fessler M.B., Abraham E. Genetic polymorphisms and sepsis. Shock 2005, 24(4):300-312.
95. Waterer G.W., Wunderink R.G. Science review: Genetic variability in the systemic inflammatory response. Crit Care 2003, 7(4):308-314.
96. Holmes C.L., Russell J.A., Walley K.R. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 2003, 124(3):1103-1115.
97. Stuber F., Klaschik S., Lehmann L.E. Cytokine promoter polymorphisms in severe sepsis. Clin Infect Dis 2005, 7(Suppl 41):S416-420.
98. Arbour N.C., Lorenz E., Schutte B.C., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25(2):187-191.
99. Schwartz D.A. The role of TLR4 in endotoxin responsiveness in humans. J Endotoxin Res 2001, 7(5):389-393.
100. Lorenz E., Mira J.P., Frees K.L., Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002, 162(9):1028-1032.
101. Agnese D.M., Calvano J.E., Hahm S.J. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002, 186(10):1522-1525.
102. Barber R.C., Chang L.Y., Arnoldo B.D., et al. Innate immunity SNPs are associated with risk for severe sepsis after burn injury. Clin Med Res 2006, 4(4):250-255.
103. Karoly E., Fekete A., Banki N.F., et al. Heat shock protein 72 (HSPA1B) gene polymorphism and Toll-like receptor (TLR) 4 mutation are associated with increased risk of urinary tract infection in children. Pediatr Res 2007, 61(3):371-374.
104. Read R.C., Pullin J., Gregory S., et al. A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001, 184(5):640-642.
105. Allen A., Obaro S., Bojang K., et al. Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr Infect Dis J 2003, 22(11):1018-1019.
106. Hubacek J.A., Stuber F., Frohlich D., et al. The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 2000, 1(6):405-407.
107. Gibot S., Cariou A., Drouet L., et al. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002, 30(5):969-973.
108. Heesen M., Bloemeke B., Schade U. The -260 C->T promoter polymorphism of the lipopolysaccharide receptor CD14 and severe sepsis in trauma patients. Intensive Care Med 2002, 28(8):1161-1163.
109. Gu W., Shan Y.A., Zhou J., et al. Functional significance of gene polymorphisms in the promoter of myeloid differentiation-2. Ann Surg 2007, 246(1):151-158.
110. Kutukculer N., Yeniay B.S., Aksu G., Berdeli A. Arg753Gln polymorphism of the human toll-like receptor-2 gene in children with recurrent febrile infections. Biochem Genet 2007, 45(7-8):507-514.
111. Tabel Y., Berdeli A., Mir S. Association of TLR2 gene Arg753Gln polymorphism with urinary tract infection in children. Int J Immunogenet 2007, 34(6):399-405.
112. Lorenz E., Mira J.P., Cornish K.L. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000, 68(11):6398-6401.
113. van Deventer S.J. Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 2000, 1(Suppl 26):S98-102.
114. Mira J.P., Cariou A., Grall F., et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. Jama 1999, 282(6):561-568.
115. Nadel S., Newport M.J., Booy R., Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996, 174(4):878-880.
116. McArthur J.A., Zhang Q., Quasney M.W. Association between the A/A genotype at the lymphotoxin-alpha+250 site and increased mortality in children with positive blood cultures. Pediatr Crit Care Med 2002, 3(4):341-344.
117. Read R.C., Cannings C., Naylor S.C., et al. Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 2003, 138(7):534-541.
118. Endler G., Marculescu R., Starkl P. Polymorphisms in the interleukin-1 gene cluster in children and young adults with systemic meningococcemia. Clin Chem 2006, 52(3):511-514.
119. Lehrnbecher T., Bernig T., Hanisch M. Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005, 19(10):1745-1750.
120. Michalek J., Svetlikova P., Fedora M., et al. Interleukin-6 gene variants and the risk of sepsis development in children. Hum Immunol 2007, 68(9):756-760.
121. Balding J., Healy C.M., Livingstone W.J., et al. Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease?. Genes Immun 2003, 4(8):533-540.
122. Artifoni L., Negrisolo S., Montini G., et al. Interleukin-8 and CXCR1 receptor functional polymorphisms and susceptibility to acute pyelonephritis. J Urol 2007, 177(3):1102-1106.
123. Westendorp R.G., Hottenga J.J., Slagboom P.E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999, 354(9178):561-563.
124. Haralambous E., Hibberd M.L., Hermans P.W., et al. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 2003, 31(12):2788-2793.
125. Geishofer G., Binder A., Muller M., et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 2005, 164(8):486-490.
126. Binder A., Endler G., Rieger S., et al. Protein C promoter polymorphisms associate with sepsis in children with systemic meningococcemia. Hum Genet 2007, 122(2):183-190.
127. van Sorge N.M., van der Pol W.L., van de Winkel J.G. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003, 61(3):189-202.
128. Bredius R.G., Derkx B.H., Fijen C.A. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994, 170(4):848-853.
129. Domingo P., Muniz-Diaz E., Baraldes M.A., et al. Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 2002, 112(1):19-25.
130. Platonov A.E., Kuijper E.J., Vershinina I.V. Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol 1998, 111(1):97-101.
131. Drogari-Apiranthitou M., Fijen C.A., Thiel S., et al. The effect of mannan-binding lectin on opsonophagocytosis of Neisseria meningitidis. Immunopharmacology 1997, 38(1-2):93-99.
132. van der Pol W.L., Huizinga T.W., Vidarsson G., et al. Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001, 184(12):1548-1555.
133. Fijen C.A., Bredius R.G., Kuijper E.J. Polymorphism of IgG Fc receptors in meningococcal disease. Ann Intern Med 1993, 119(7 Pt 1):636.
134. Yee A.M., Phan H.M., Zuniga R., et al. Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000, 30(1):25-28.
135. Yuan F.F., Wong M., Pererva N., et al. FcgammaRIIA polymorphisms in Streptococcus pneumoniae infection. Immunol Cell Biol 2003, 81(3):192-195.
136. Summerfield J.A., Sumiya M., Levin M., Turner M.W. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. Bmj 1997, 314(7089):1229-1232.
137. Hibberd M.L., Sumiya M., Summerfield J.A. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999, 353(9158):1049-1053.
138. Koch A., Melbye M., Sorensen P. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. Jama 2001, 285(10):1316-1321.
139. Gomi K., Tokue Y., Kobayashi T. Mannose-binding lectin gene polymorphism is a modulating factor in repeated respiratory infections. Chest 2004, 126(1):95-99.
140. Roy S., Knox K., Segal S., et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002, 359(9317):1569-1573.
141. Fidler K.J., Wilson P., Davies J.C., et al. Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin. Intensive Care Med 2004, 30(7):1438-1445.
142. Michalek J., Svetlikova P., Fedora M. Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med 2007, 33(12):2158-2164.
143. Levin M., Quint P.A., Goldstein B., et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000, 356(9234):961-967.
144. Stalets E., Wong H.R. Critically associating. Crit Care Med 2009, 37(4):1492-1493.
145. Wong H.R., Shanley T.P., Sakthivel B., et al. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics 2007, 30(2):146-155.
146. Rink L., Haase H. Zinc homeostasis and immunity. Trends Immunol 2007, 28(1):1-4.
147. Knoell D.L., Julian M.W., Bao S., et al. Zinc deficiency increases organ damage and mortality in a murine model of polymicrobial sepsis. Crit Care Med 2009, 37(4):1380-1388.
148. Shanley T.P., Cvijanovich N., Lin R., et al. Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock. Mol Med 2007, 13(9-10):495-508.
149. Mosser D.M., Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008, 226:205-218.
150. Ayala A., Chaudry I.H. Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock 1996, 1(Suppl 6):S27-38.
151. Hotchkiss R.S., Tinsley K.W., Karl I.E. Role of apoptotic cell death in sepsis. Scand J Infect Dis 2003, 35(9):585-592.
152. Hotchkiss R.S., Coopersmith C.M., Karl I.E. Prevention of lymphocyte apoptosis-a potential treatment of sepsis?. Clin Infect Dis 2005, 7(Suppl 41):S465-469.
153. Cvijanovich N., Shanley T.P., Lin R., et al. Validating the genomic signature of pediatric septic shock. Physiol Genomics 2008, 34(1):127-134.
154. Wong H.R., Cvijanovich N., Allen G.L., et al. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med 2009, 37(5):1558-1566.
155. Wong H.R., Cvijanovich N., Lin R., et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 2009, 7:34.
156. Brierley J., Carcillo J.A., Choong K., et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009, 37(2):666-688.
157. Jabre P., Combes X., Lapostolle F., et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009, 374(9686):293-300.
158. Tekwani K.L., Watts H.F., Rzechula K.H. A prospective observational study of the effect of etomidate on septic patient mortality and length of stay. Acad Emerg Med 2009, 16(1):11-14.
159. Carcillo J.A., Davis A.L., Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. Jama 1991, 266(9):1242-1245.
160. Han Y.Y., Carcillo J.A., Dragotta M.A., et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 2003, 112(4):793-799.
161. Oliveira C.F., Nogueira de Sa F.R., Oliveira D.S. Carcillo JA: Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world. Pediatr Emerg Care 2008, 24(12):810-815.
162. de Oliveira C.F., de Oliveira D.S., Gottschald A.F., et al. ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation. Intensive Care Med 2008, 34(6):1065-1075.
163. Rivers E., Nguyen B., Havstad S. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345(19):1368-1377.
164. Perez A.C., Eulmesekian P.G., Minces P.G., Schnitzler E.J. Adequate agreement between venous oxygen saturation in right atrium and pulmonary artery in critically ill children. Pediatr Crit Care Med 2009, 10(1):76-79.
165. Oliveira C.F., Troster E.J., Vaz F.A. Description of technique for continuous monitoring of central venous oxygen saturation in infants and children with septic shock. Revista Brasileria Terapia Intensiva 2005, 17:305-308.
166. Fernandez E.G., Green T.P., Sweeney M. Low inferior vena caval catheters for hemodynamic and pulmonary function monitoring in pediatric critical care patients. Pediatr Crit Care Med 2004, 5(1):14-18.
167. Magder S. Central venous pressure: a useful but not so simple measurement. Crit Care Med 2006, 34(8):2224-2227.
168. Kumar A., Anel R., Bunnell E., et al. Pulmonary artery occlusion pressure and central venous pressure fail to predict ventricular filling volume, cardiac performance, or the response to volume infusion in normal subjects. Crit Care Med 2004, 32(3):691-699.
169. Vincent J.L., Weil M.H. Fluid challenge revisited. Crit Care Med 2006, 34(5):1333-1337.
170. Hadian M., Pinsky M.R. Functional hemodynamic monitoring. Curr Opin Crit Care 2007, 13(3):318-323.
171. Reinhart K., Kuhn H.J., Hartog C., Bredle D.L. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Intensive Care Med 2004, 30(8):1572-1578.
172. Dueck M.H., Klimek M., Appenrodt S. Trends but not individual values of central venous oxygen saturation agree with mixed venous oxygen saturation during varying hemodynamic conditions. Anesthesiology 2005, 103(2):249-257.
173. Kim J.J., Dreyer W.J., Chang A.C. Arterial pulse wave analysis: An accurate means of determining cardiac output in children. Pediatr Crit Care Med 2006, 7(6):532-535.
174. Calamandrei M., Mirabile L., Muschetta S. Assessment of cardiac output in children: a comparison between the pressure recording analytical method and Doppler echocardiography. Pediatr Crit Care Med 2008, 9(3):310-312.
175. Richard C., Warszawski J., Anguel N., et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. Jama 2003, 290(20):2713-2720.
176. Greenberg S.B., Murphy G.S., Vender J.S. Current use of the pulmonary artery catheter. Curr Opin Crit Care 2009, 15(3):249-253.
177. Bochud P.Y., Bonten M., Marchetti O., Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004, 32(Suppl 11):S495-512.
178. Garnacho-Montero J., Aldabo-Pallas T., Garnacho-Montero C. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 2006, 10(4):R111.
179. Barton P., Garcia J., Kouatli A. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest 1996, 109(5):1302-1312.
180. Lindsay C.A., Barton P., Lawless S. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. J Pediatr 1998, 132(2):329-334.
181. Delgado A.F., Okay T.S., Leone C. Hospital malnutrition and inflammatory response in critically ill children and adolescents admitted to a tertiary intensive care unit. Clinics (Sao Paulo) 2008, 63(3):357-362.
182. Marik P.E., Zaloga G.P. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med 2001, 29(12):2264-2270.
183. Krejci V., Hiltebrand L.B., Sigurdsson G.H. Effects of epinephrine, norepinephrine, and phenylephrine on microcirculatory blood flow in the gastrointestinal tract in sepsis. Crit Care Med 2006, 34(5):1456-1463.
184. Santiago M.J., Lopez-Herce J., Urbano J. Complications of continuous renal replacement therapy in critically ill children: a prospective observational evaluation study. Crit Care 2009, 13(6):R184.
185. Joannidis M. Continuous renal replacement therapy in sepsis and multisystem organ failure. Semin Dial 2009, 22(2):160-164.
186. Bellomo R., Cass A., Cole L., et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009, 361(17):1627-1638.
187. Hirshberg E., Larsen G., Van Duker H. Alterations in glucose homeostasis in the pediatric intensive care unit: Hyperglycemia and glucose variability are associated with increased mortality and morbidity. Pediatr Crit Care Med 2008, 9(4):361-366.
188. Day K.M., Haub N., Betts H., Inwald D.P. Hyperglycemia is associated with morbidity in critically ill children with meningococcal sepsis. Pediatr Crit Care Med 2008, 9(6):636-640.
189. van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345(19):1359-1367.
190. Wiener R.S., Wiener D.C., Larson R.J. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. Jama 2008, 300(8):933-944.
191. Finfer S., Chittock D.R., Su S.Y., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360(13):1283-1297.
192. Brunkhorst F.M., Engel C., Bloos F., et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358(2):125-139.
193. Vlasselaers D., Milants I., Desmet L., et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet 2009, 373(9663):547-556.
194. Bone R.C., Fisher C.J., Clemmer T.P., et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987, 317(11):653-658.
195. Sprung C.L., Caralis P.V., Marcial E.H. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984, 311(18):1137-1143.
196. Pizarro C.F., Troster E.J., Damiani D., Carcillo J.A. Absolute and relative adrenal insufficiency in children with septic shock. Crit Care Med 2005, 33(4):855-859.
197. Sarthi M., Lodha R., Vivekanandhan S., Arora N.K. Adrenal status in children with septic shock using low-dose stimulation test. Pediatr Crit Care Med 2007, 8(1):23-28.
198. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Jama 2002, 288(7):862-871.
199. Sprung C.L., Annane D., Keh D., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358(2):111-124.
200. Mason P.E., Al-Khafaji A., Milbrandt E.B., et al. CORTICUS: the end of unconditional love for steroid use?. Crit Care 2009, 13(4):309.
201. Valoor H.T., Singhi S., Jayashree M. Low-dose hydrocortisone in pediatric septic shock: an exploratory study in a third world setting. Pediatr Crit Care Med 2009, 10(1):121-125.
202. Markovitz B.P., Goodman D.M., Watson R.S. A retrospective cohort study of prognostic factors associated with outcome in pediatric severe sepsis: what is the role of steroids?. Pediatr Crit Care Med 2005, 6(3):270-274.
203. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13(5):552-559.
204. Schefold J.C., Hasper D., Volk H.D., Reinke P. Sepsis: time has come to focus on the later stages. Med Hypotheses 2008, 71(2):203-208.
205. Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp 2007, 280:21-27.
206. Turrel F., Guignant C., Venet F., et al. Innovative therapeutic strategies for restoring lymphocyte functions in septic patients. Inflamm Allergy Drug Targets 2008, 7(3):181-186.
207. Marshall J.C. Sepsis: rethinking the approach to clinical research. J Leukoc Biol 2008, 83(3):471-482.
208. Warren H.S., Elson C.M., Hayden D.L., et al. A genomic score prognostic of outcome in trauma patients. Mol Med 2009, 15(7-8):220-227.
209. Nowak J.E., Wheeler D.S., Harmon K.K., Wong H.R. Admission chemokine (C-C motif) ligand 4 levels predict survival in pediatric septic shock. Pediatr Crit Care Med 2010, 11(2):213-216.